Heterodimeric Antibody Assembly With Electrostatic Chain Pairing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in producing heterodimeric antibodies lies in achieving robust and homogeneous pairing of heavy and light chains, as existing methods result in random pairings and mispaired contaminants, which complicates manufacturing and biological efficacy.
Innovation Solution
Engineering electrostatic steering mechanisms by mutating interface residues in heavy and light chains to favor correct pairing, using specific amino acid substitutions at positions 39, 147, and 165 for VH and CH1 domains, and positions 38, 124, and 169/170 for VL and CL domains, creating electrostatically favorable interfaces for heterodimerization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If heavy and light chains are co-expressed in the same cell to assemble heterodimeric antibodies, then productivity is improved, but manufacturing precision deteriorates due to random pairing and mispaired contaminants
Solution Approach 1:
The patent applies parameter changes by modifying the electrostatic properties of the heavy and light chain interfaces. Specific amino acid substitutions are made at defined positions (VH: 39, 147, 165; VL: 38, 124, 169/170) to create complementary charge patterns that guide correct pairing. This transforms the random pairing process into an electrostatically directed assembly process, achieving both high productivity and manufacturing precision.
2Manufacturing precision
If electrostatic steering mechanisms are engineered at the heavy-light chain interface, then manufacturing precision is improved, but device complexity increases due to multiple amino acid substitutions required
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions only at specific positions in the heavy and light chain interfaces where electrostatic steering is needed. Rather than modifying the entire protein structure, the invention focuses local modifications at the critical interface regions (VH positions 39, 147, 165 and VL positions 38, 124, 169/170), thereby achieving high pairing homogeneity with minimal complexity.
3Reliability
If interface residues are mutated to create electrostatic steering mechanisms, then reliability is improved, but loss of substance increases due to potential loss of binding at CDR contacts
Solution Approach 1:
The patent applies segmentation by separating the antibody interface into distinct functional regions: the CDR contact regions and the electrostatic steering interface regions. By placing charged residues at specific positions (VH: 39, 147, 165; VL: 38, 124, 169/170) that are spatially separated from the CDRs, the invention ensures that electrostatic steering and antigen binding functions are performed by different residue sets, thereby achieving high pairing fidelity without compromising binding affinity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach stabilizes the protein structure, reduces interface destabilization, and facilitates high-throughput screening for correct heavy-light chain pairing, enhancing manufacturing efficiency and biological efficacy.
Implementation Method 1
charged residues at the end of the VH and VL domains and at the beginning and end of CH1 and CL domains were introduced... creating salt bridges at the ends of the domains and thereby generating a 'clip-effect' that closes the correct heavy-light chain formation
Data Source
AI summary
The present invention provides heterodimeric antibodies and fragments thereof and methods for their preparation, wherein the pairing of heavy and light chains has been improved. Interface residues were mutated such that each light chain strongly favoured its cognate heavy chain when two different heavy chains and two different light chains were co-transfected and co-expressed in the same cell to assemble a functional, heterodimeric antibody or fragment thereof.